First clinical experience with 6 Mercaptopurine powder for oral suspension PREVALLTM for maintenance therapy in Pediatric Acute lymphoblastic leukemia

First clinical experience with 6 Mercaptopurine powder for oral suspension PREVALLTM for maintenance therapy in Pediatric Acute lymphoblastic leukemia | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL British Journal of Clinical Pharmacology This is a preprint and has not been peer reviewed. Data may be preliminary. 12 May 2026 V1 Latest version Share on First clinical experience with 6 Mercaptopurine powder for oral suspension PREVALLTM for maintenance therapy in Pediatric Acute lymphoblastic leukemia Authors : Chetan Dhamne 0000-0002-3637-2880 [email protected] , Rangasai Anirudh Neeli [email protected] , Naman Agrawal [email protected] , Ninad Dhumak [email protected] , Nirmalya Roy [email protected] , Shyam Srinivasan [email protected] , Akanksha Chichra [email protected] , Girish Chinnaswamy [email protected] , Gaurav Narula [email protected] , Shripad Banavali [email protected] , and Vikram Gota [email protected] Authors Info & Affiliations https://doi.org/10.22541/authorea.15003115/v1 13 views 6 downloads Contents Abstract Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Optimal myelosuppression with oral 6-Mercaptopurine and Methotrexate is the cornerstone of ALL maintenance. 6MP powder for oral suspension (PFOS) was launched in India by IDRS labs showed 47% higher oral bioavailability compared to the reference 50mg tablet formulation in healthy adult volunteers. A 20% dose reduction was recommended based on PopPK modelling. In this retrospective study we reviewed absolute neutrophil counts over 24 weeks to assess whether the model informed dose achieved optimal myelosuppression in children on maintenance therapy who were either switched to or started on PREVALL TM suspension at 80% of the recommended tablet dose. Our analysis showed that PREVALL TM suspension at 80% of the tablet dose is suits about 50% children on ALL maintenance therapy. We recommend this dose as a starting dose for children receiving 6MP PFOS. Further prospective studies are needed to validate these findings. Children with NUDT15/TPMT mutation could receive doses as low as 2 mg daily giving sustained stable exposure of 6MP. Information & Authors Information Version history V1 Version 1 12 May 2026 Collection British Journal of Clinical Pharmacology Authors Affiliations Chetan Dhamne 0000-0002-3637-2880 [email protected] View all articles by this author Rangasai Anirudh Neeli [email protected] View all articles by this author Naman Agrawal [email protected] Tata Memorial Hospital, Mumbai, India, 400012 View all articles by this author Ninad Dhumak [email protected] View all articles by this author Nirmalya Roy [email protected] View all articles by this author Shyam Srinivasan [email protected] View all articles by this author Akanksha Chichra [email protected] View all articles by this author Girish Chinnaswamy [email protected] View all articles by this author Gaurav Narula [email protected] View all articles by this author Shripad Banavali [email protected] View all articles by this author Vikram Gota [email protected] View all articles by this author Metrics & Citations Metrics Article Usage 13 views 6 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Chetan Dhamne, Rangasai Anirudh Neeli, Naman Agrawal, et al. First clinical experience with 6 Mercaptopurine powder for oral suspension PREVALLTM for maintenance therapy in Pediatric Acute lymphoblastic leukemia. Authorea . 12 May 2026. DOI: https://doi.org/10.22541/authorea.15003115/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/authorea.15003115/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9fe1a872596e0700',t:'MTc3OTE3ODU3MA=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();